Drug Trial Radar · NCT06535841
A First-in-Human Safety Trial of MTX-474
Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jul 10, 2024
Primary completion
Apr 24, 2025
Study completion Apr 24, 2025
Sponsor
- Lead sponsor
- Mediar TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-474 administered in healthy adults.
Conditions
- Healthy
Interventions
MTX-474Biological
MTX-474 is an immunoglobin G1 (IgG1) monoclonal antibody directed against Ephrin B2 that binds to and has demonstrated ability to block phosphorylation of its preferred receptor EphB4. Increased levels of circulating soluble EphrinB2 have been found in patients with systemic sclerosis.
PlaceboOther
Matching Placebo - Normal Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Related Adverse Events in healthy volunteersTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
- MTX-474 PK by dose will be evaluated for Cmax, as feasibleTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
- Serum sample results will be summarized for presence of Anti-Drug Antibodies during the SAD and MAD portions of the studyTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
- MTX-474 PK by dose will be evaluated for AUC0-t, as feasibleTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
- MTX-474 PK by dose will be evaluated for AUC0-tau (MAD only), as feasibleTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
- MTX-474 PK by dose will be evaluated for AUC0-∞, as feasibleTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Herston, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.